An interventional study of Anodal tDCS and Sham tDCS in Stroke, sponsored by Tan Tock Seng Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Tan Tock Seng Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Stroke by Tan Tock Seng Hospital — 3 open to participants now, 6 under way, none of them phase 3. Stroke · Tan Tock Seng Hospital.
Among the 29 studies in Stroke by Tan Tock Seng Hospital, this one is the 2nd largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, and was the 28th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →3 of the 29 studies in Stroke by Tan Tock Seng Hospital are open now, in 1 country. Recruiting first, the newest first:
Tan Tock Seng Hospital · Sites in Singapore
Ages 50+
Tan Tock Seng Hospital
Ages 21–80
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 50 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 17 across the 20 interventional studies, 52 across the 9 observational. Of the 22 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tan Tock Seng Hospital is the lead sponsor of 108 studies on the registry; 19 are open to participants now.
3 of the studies in Stroke by Tan Tock Seng Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06704997Tan Tock Seng HospitalMachine Learning to Predict Factors Affecting Rehabilitation Length of Stay and Healthcare Costs for Neurological Rehabilitation | 2026-12-31 |
| NCT06073106Tan Tock Seng HospitalTargeting Osteosarcopaenia and Multimorbidity for Frailty Prevention | 2027-01 |
| NCT07122752Tan Tock Seng HospitalFeasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy | 2027-08-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies in Stroke by Tan Tock Seng Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a randomized, blinded, sham-controlled trial. The medical device used, Soterix Medical 1x1 tDCS stimulator, is capable of delivering either real or sham tDCS and has been used in many randomised controlled trials in stroke patients.
50 patients with subacute stroke and severe upper limb weakness within 8 weeks of stroke on transfer to TTSH stroke rehab wards will be recruited over a period of 10 months. Recruited patients will be randomized into the intervention and control arms in a 1:1 ratio.
The primary objective is to determine the clinical efficacy, technical feasibility and safety of anodal tDCS therapy to the unaffected hemisphere in hospitalized subacute stroke patients with severe arm weakness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anodal tDCS to contralateral dorsal premotor cortex (dPMc)
Device: Anodal tDCS
Sham tDCS to contralateral dorsal premotor cortex (dPMc)
Device: Sham tDCS
This anodal tDCS is applied over the contralateral dorsal premotor cortex (instead of the ipsilateral motor cortex in previous studies).
Also known as: tDCS
Sham tDCS is applied
Also known as: tdcs
Fugl-Meyer Upper Limb
Fugl-Meyer Upper Limb
Time frame: At baseline (Day 0) At end of 10 tDCS sessions (Day 10) At 3 months after the 10th tDCS session (Month 3)
Streamlined Wolf Motor Function Test (sWMFT)
Streamlined Wolf Motor Function Test (sWMFT)
Time frame: At baseline (Day 0) At end of 10 tDCS sessions (Day 10) At 3 months after the 10th tDCS session (Month 3)
Functional Independence Measure (FIM)
Functional Independence Measure (FIM) is a widely used objective assessment tool in rehabilitation to evaluate a patient's functional abilities and track their progress. It is a 18-item, 7-level scale, with higher scores indicating greater independence. The total FIM score ranges from 18 to 126.
Time frame: At baseline (Day 0) At end of 10 tDCS sessions (Day 10)
EQ5D-5L
The EurolQol 5-Dimension 5-Level (EQ5D-5L) is a widely-used, non-disease specific questionnaire designed to assess a patient's health related quality of life. It serves as a patient-reported outcome instrument, capturing the patient's own perspective on their health. It consists of a descriptive system of five questions (each scored from Level 1 to 5, with a higher score indicating more severe problems) and a visual analogue scale (VAS) for overall health assessment. A higher VAS (from 0 to 100) would indicate a better quality of life.
Time frame: At baseline (Day 0) and at 3 months after the 10th tDCS session (Month 3)
Rate of Adverse Events from tDCS
An adverse events questionnaire is administered immediately after each tDCS session. As such, each participant would fill up 10 adverse effects questionnaires after a total of 10 tDCS sessions. The rate of adverse events from tDCS would be computed from the number of adverse events divided by the total number of tDCS sessions.
Time frame: Immediately after each tDCS session (total 10 sessions of tDCS)
Plan to share: No — To protect the privacy of participants. Preparing IPD for sharing can also be time-consuming and resource-intensive.
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Sep 2026, 12 months later.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 12 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.